Peptide stacks

A cheat sheet of 46 peptide combinations organised by research goal, each graded for evidence.

A peptide stack is two or more peptides used together because they act on different mechanisms relevant to one goal. Most named stacks — Wolverine, GLOW, KLOW — come from research-community practice and vendor marketing rather than from studies of the combination. Individual components may have preclinical or human data; the combinations themselves almost never do.

Each entry below lists what is in the combination, the proposed rationale for pairing those compounds, an evidence grade for the combination itself, and an explicit statement of what has not been established. Every peptide name links to its full profile in the peptide library. Concentrations for multiple compounds in a shared vial can be worked out with the peptide calculator, and the dose reported for each component on its own is in the peptide dosage chart.

For research use only. Not medical advice. This page contains no dosing or administration guidance, and no combination listed here is an established protocol.

How the evidence grades work

Every combination below carries one of four grades. The grade describes the evidence for the combination as listed, not for its ingredients individually — a stack of two well-studied compounds that has never been trialled together does not inherit their evidence.

Evidence grades used on this page, what each means, and how many of the catalogued peptide combinations carry it
Grade	What it means	Stacks
Human data on the combination	The combination itself has been tested in controlled human trials, not just its ingredients separately. Only one entry on this page meets this bar.	1
Human data on each component	Every compound in the stack has controlled human data on its own. Nothing is known about what happens when they are used together, including whether the effects add up.	3
Preclinical evidence only	At least one component has been studied only in animals or cell culture. Animal tissue-repair and metabolic results have historically translated poorly to humans.	36
Community practice only	The pairing comes from research-community discussion and mechanistic reasoning. There is no controlled data on the combination, and for at least one component there is little controlled data of any kind.	6

The most searched named stacks

5 combinations have acquired names of their own and are searched for by name. Composition varies between suppliers for most of them, so the name alone does not tell you what is in a vial.

The Wolverine stack (BPC-157 + TB-500)

The Wolverine stack is a community nickname for the combination of BPC-157 and TB-500, named after the comic-book character’s rapid healing rather than after any clinical protocol.

Preclinical evidence onlyBPC-157 TB-500

The name is informal and the composition is not fixed. Most sources — vendors, forums and clinics alike — use it for the two-compound pairing of BPC-157 and TB-500. Some clinics market a four-compound version that adds CJC-1295 and ipamorelin under the same name, so the label alone does not tell you what is in a vial.

BPC-157 is a synthetic 15-amino-acid sequence derived from a protein found in gastric juice. Its research literature is substantial in volume but almost entirely rodent-based, covering tendon, ligament, muscle and gut injury models, with angiogenesis and growth-factor receptor expression proposed as mechanisms. TB-500 is a synthetic fragment related to thymosin beta-4, a naturally occurring actin-sequestering protein; the preclinical interest concerns cell migration and wound closure.

The proposed rationale for pairing them is that they act on different limbs of the same repair process rather than duplicating each other. That reasoning is coherent, and it is the reason the combination became popular. It is not the same thing as evidence that the combination works.

What does not exist: a controlled human trial of either compound for tissue repair, any human data on the two used together, and any established dosing derived from human pharmacokinetics. Thymosin beta-4 itself — the parent protein, not TB-500 — did reach human trials for dry eye and cardiac indications, and those results were mixed. Neither compound is approved for human use in the US, and both appear on the WADA prohibited list.

Full profile and references →In-depth guide →BPC-157 + TB-500 (the "Wolverine" pairing)GH secretagogues + tissue repair

The GLOW stack (GHK-Cu + BPC-157 + TB-500)

GLOW commonly refers to a premixed blend of GHK-Cu, BPC-157 and TB-500, sold in a single vial and named for its reported effects on skin appearance alongside tissue repair.

Preclinical evidence onlyGHK-Cu BPC-157 TB-500

GLOW is a market name rather than a defined formulation. The three-compound composition above is what almost every supplier means by it, but the ratios differ between vendors and are frequently undisclosed, so two vials labelled GLOW are not necessarily equivalent.

The addition that distinguishes GLOW from the Wolverine pairing is GHK-Cu, a naturally occurring copper-binding tripeptide first isolated from human plasma. Of everything discussed on this page, GHK-Cu has the most credible human evidence — but that evidence is dermatological and topical, from cosmetic studies of creams and serums measuring skin thickness, elasticity and appearance. It does not establish anything about injected GHK-Cu, and it does not transfer to the other two compounds in the vial.

One practical question comes up repeatedly in research discussion and is not settled by any published work: whether the three compounds are chemically stable together. GHK-Cu solutions are acidic and carry a bound copper ion, and copper can catalyse oxidation of peptide chains. Whether BPC-157 and TB-500 remain intact in a shared vial over a storage period has not been demonstrated either way. Anyone treating premixed stability as a solved problem is going beyond the evidence.

GLOW is also the reason "why is my peptide blue" is a common question — the colour comes from the copper in GHK-Cu, not from a dye or a contaminant.

Full profile and references →In-depth guide →GLOW (GHK-Cu + BPC-157 + TB-500)GLOW + cellular ageing GLOW + GH axis

The KLOW stack (GLOW + KPV)

KLOW is the GLOW blend with KPV added: GHK-Cu, BPC-157, TB-500 and KPV in one vial. The K at the front of the name is the KPV.

Preclinical evidence onlyGHK-Cu BPC-157 TB-500 KPV

The difference between GLOW and KLOW is one compound. GLOW is GHK-Cu + BPC-157 + TB-500; KLOW is the same three plus KPV. Everything true of GLOW’s composition variability and stability questions is also true of KLOW, with a fourth compound in the vial.

KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone — lysine-proline-valine. Its research interest is anti-inflammatory: it has been investigated in cell and rodent models of colitis and inflammatory skin conditions, where it appears to act without the pigmentation effects of the full alpha-MSH molecule. The proposed rationale for adding it is an inflammation-resolution arm that the GLOW combination lacks.

That preclinical work is genuine but narrow, and much of it concerns oral or topical delivery to gut and skin rather than systemic injection. There is no published human trial of KPV for any indication, and no study of any kind on the four-compound blend.

KLOW is typically blue for the same reason GLOW is — the copper in GHK-Cu. Colour is not an indicator of potency, purity or correct formulation.

Full profile and references →In-depth guide →KLOW (GLOW + KPV)Cartilage and connective tissue

CJC-1295 + Ipamorelin

CJC-1295 and ipamorelin are combined because they raise growth hormone through two different receptors: CJC-1295 is a GHRH analogue and ipamorelin a selective ghrelin-receptor agonist.

Preclinical evidence onlyCJC-1295 Ipamorelin

This is the most mechanistically well-grounded pairing in common use. GHRH analogues and ghrelin-receptor agonists act on separate receptors on the pituitary somatotroph, and the combination produces a larger GH response than either alone — an effect demonstrated in human endocrine research, though with the parent compounds rather than these specific analogues.

The DAC distinction matters and is a frequent source of confusion. CJC-1295 with DAC (drug affinity complex) binds serum albumin, extending its half-life to roughly a week and producing a sustained elevation in GH and IGF-1 — a "bleed" rather than a pulse. CJC-1295 without DAC, often sold as modified GRF(1-29), acts over minutes to hours and is chosen when the intent is to preserve the body’s natural pulsatile GH pattern. These behave differently enough that they should not be treated as interchangeable, and most stack discussions that specify "no DAC" are doing so deliberately.

Ipamorelin’s appeal in this pairing is selectivity: unlike earlier GH secretagogues such as GHRP-6 and GHRP-2, it produces comparatively little cortisol, prolactin or appetite stimulation, which is why it displaced them in community protocols.

What the evidence supports is that this combination raises growth hormone. What it does not establish is that raising GH in healthy adults produces the outcomes it is usually stacked for — improved body composition, faster injury recovery, better sleep or slower ageing. Growth-hormone elevation is a measurable intermediate, not an outcome, and the trade-offs (insulin sensitivity in particular) are real. Neither compound is approved for human use.

Full profile and references →In-depth guide →GH secretagogues + tissue repair GH axis + mitochondrial signalling GH axis + cellular ageing

CagriSema (cagrilintide + semaglutide) — what a tested combination looks like

CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a GLP-1 receptor agonist. It is the only combination on this page that has been evaluated as a combination in phase-3 human trials.

Human data on the combinationCagrilintide Semaglutide

This entry is here for contrast. Every other combination on this page is graded on the evidence for its individual components, because the combination itself has never been tested. CagriSema is the exception, and the difference is worth seeing directly.

Semaglutide and cagrilintide act on different satiety pathways — GLP-1 receptor agonism and amylin receptor agonism respectively — which is exactly the kind of complementary-mechanism reasoning used to justify every other stack here. The difference is that this pairing was then taken through a phase-3 programme (REDEFINE) with pre-registered endpoints, a comparator, thousands of participants and published results, rather than being inferred from mechanism and adopted.

The results were also instructive: the combination produced substantial weight loss but came in below some analyst expectations, which is the sort of outcome that only becomes visible when a combination is actually tested. Mechanistic plausibility had not predicted the magnitude.

CagriSema is not FDA-approved as of this page’s review date. Gastrointestinal adverse effects are common across this drug class. Research-market or compounded versions are not the formulation that was trialled, and nothing about the trial results transfers to them.

Full profile and references →In-depth guide →Cagrilintide + Semaglutide (CagriSema)Incretin + mitochondrial recomposition

The cheat sheet: 46 combinations by goal

Filter by research goal, or scroll through all eight categories.

Recovery and tissue-repair stacks (9)

The largest cluster of community combinations, and the one behind the Wolverine, GLOW and KLOW names. Almost all of the underlying tissue-repair evidence is preclinical.

BPC-157 + TB-500 (the "Wolverine" pairing)

Preclinical evidence only

The most widely discussed pairing in the research-peptide community. The proposed rationale is that the two act on different parts of the same repair process: BPC-157 has been investigated in rodent models for angiogenesis and tendon-to-bone healing, while TB-500, a synthetic fragment related to thymosin beta-4, has been studied for actin sequestration and cell migration. Combining them is an attempt to cover both signalling and structural arms.

What is not established: Neither compound has completed a controlled human efficacy trial for tissue repair, and the pair has never been studied together in humans. Almost all supporting data is rodent work, much of it from a small number of research groups.

GLOW (GHK-Cu + BPC-157 + TB-500)

Preclinical evidence only

Sold pre-mixed as a single vial under the GLOW name. The proposed rationale adds GHK-Cu, a naturally occurring copper-binding tripeptide with human cosmetic-dermatology data on collagen and skin remodelling, to the BPC-157 + TB-500 pairing, aiming at skin and connective tissue alongside soft-tissue repair.

What is not established: GLOW is a market name, not a standardised formulation — ratios vary between suppliers and are rarely disclosed. The three-compound combination has not been studied. GHK-Cu’s human evidence is topical and cosmetic; it does not transfer to injected use.

Interaction note: Researchers have raised a stability question about premixed blends: GHK-Cu solutions are acidic and copper-bound, and it is not established that BPC-157 and TB-500 remain intact alongside them in a shared vial over time. No published compatibility study settles this.

KLOW (GLOW + KPV)

Preclinical evidence only

KLOW is GLOW with KPV added — the K is the addition. KPV is the C-terminal tripeptide of alpha-MSH and has been investigated in animal and cell models for anti-inflammatory signalling, particularly in the gut. The proposed rationale is an additional inflammation-resolution arm on top of the GLOW combination.

What is not established: The four-compound blend has no published data of any kind. KPV’s literature is preclinical and mostly concerns oral or topical gut and skin models rather than systemic use. Composition varies between suppliers.

Interaction note: The same premix stability question that applies to GLOW applies here, with a fourth compound added to the vial.

GH secretagogues + tissue repair

Preclinical evidence only

Pairs the growth-hormone axis with the tissue-repair pairing. CJC-1295 is a GHRH analogue and ipamorelin a selective ghrelin-receptor agonist; combining a GHRH analogue with a GH secretagogue is a well-described way to raise pulsatile GH release. The proposed rationale is that a higher GH and IGF-1 background supports the repair processes the other two compounds are thought to act on.

What is not established: Raising GH is measurable; that it improves tendon or ligament healing outcomes in humans is not established. None of the four-compound combination has been studied, and BPC-157 and TB-500 remain preclinical.

Sermorelin + tissue repair

Preclinical evidence only

A variant of the GH-axis approach using sermorelin, a shorter GHRH analogue that was formerly an approved diagnostic and paediatric growth product, in place of CJC-1295. It is discussed as the more conservative GHRH choice because of that regulatory history and its shorter half-life.

What is not established: Sermorelin’s human data concerns growth-hormone stimulation, not tissue repair or recovery outcomes. The combination is untested.

Mitochondrial support + repair

Preclinical evidence only

Adds SS-31 (elamipretide), a mitochondria-targeting tetrapeptide that binds cardiolipin and has been through human trials in primary mitochondrial myopathy and other indications, to a GH-axis and repair combination. The proposed rationale is that recovery from heavy training load is partly a mitochondrial problem.

What is not established: Elamipretide’s trials targeted mitochondrial disease populations, and several missed their primary endpoints. Extrapolating to training recovery in healthy people is not supported, and the combination is untested.

Neuro-repair + soft tissue

Preclinical evidence only

Discussed in the context of concussion and nerve-adjacent injury rather than pure musculoskeletal repair. Semax is an ACTH(4-10) analogue used clinically in Russia for stroke and cognitive indications, and has been investigated for BDNF expression; the remaining three are the GLOW-style repair group.

What is not established: Semax’s clinical record is almost entirely Russian-language and has not been replicated in Western trials. No data exists on this combination, and nothing here should be read as applicable to head injury.

Gut barrier and mucosal research

Preclinical evidence only

A distinct target from the musculoskeletal stacks. LL-37 is the human cathelicidin antimicrobial peptide, KPV has been investigated in colitis models, and BPC-157’s original rodent literature is gastrointestinal. The proposed rationale is barrier integrity plus inflammation resolution.

What is not established: All four are preclinical for this use. LL-37 is also immunologically active in ways that are not straightforwardly beneficial — it has been implicated in autoimmune skin conditions — so "more" is not obviously better.

Cartilage and connective tissue

Community practice only

The joint- and cartilage-oriented combination in this category. Cartalax is a short synthetic peptide from the Khavinson bioregulator series proposed to act on cartilage extracellular matrix; it is combined here with a GHRH analogue and mitochondrial peptides.

What is not established: The Khavinson peptide literature is narrow, largely from one group, and has not been independently replicated. There is no controlled human data on Cartalax for joint outcomes and none at all on this combination.

Longevity and cellular-ageing stacks (7)

Combinations built around mitochondrial-derived peptides and telomere-related compounds. Human outcome data on ageing endpoints does not exist for any of these pairings.

Epitalon + MOTS-C + Humanin

Preclinical evidence only

The core longevity combination in community discussion. MOTS-C and Humanin are mitochondrial-derived peptides whose circulating levels decline with age and which have been investigated for metabolic and cytoprotective signalling; Epitalon is a Khavinson tetrapeptide studied in relation to telomerase and pineal function. The proposed rationale is nuclear and mitochondrial ageing pathways addressed together.

What is not established: No human lifespan or healthspan trial exists for any of the three, let alone the combination. The Epitalon telomerase work is in vitro and in small, methodologically limited human cohorts from a single research lineage. Declining biomarker levels with age do not establish that restoring them helps.

Epitalon + MOTS-C + Humanin + GHK-Cu

Preclinical evidence only

The preceding combination with GHK-Cu added for skin and extracellular-matrix effects, on the reasoning that visible ageing and cellular ageing are being targeted together. GHK-Cu also declines measurably with age in plasma.

What is not established: Adds GHK-Cu’s evidence gap to the previous entry’s: its human data is topical cosmetic work on skin appearance, which says nothing about systemic ageing. The four-compound combination is unstudied.

Mitochondrial protection + repair signalling

Preclinical evidence only

Built around elamipretide (SS-31), the compound in this category with the most substantial human trial programme, combined with NAD+ for redox and sirtuin substrate availability and Humanin for mitochondrial stress signalling.

What is not established: Elamipretide’s trials were in mitochondrial disease, not ageing, and results were mixed. NAD+ precursor trials in humans have reliably raised NAD+ levels without yet demonstrating clear functional outcomes. The combination is untested.

GH axis + cellular ageing

Community practice only

Layers a GH-secretagogue pair onto the cellular-ageing group, on the reasoning that GH and IGF-1 decline with age alongside the other markers being targeted.

What is not established: This is the combination most in tension with the underlying biology it cites: reduced GH/IGF-1 signalling is associated with extended lifespan across several model organisms, so raising it is not an obvious longevity strategy. Five compounds, none studied together.

Interaction note: CJC-1295 and ipamorelin act on the same axis by different receptors — that overlap is the point, but it also means GH effects are not independent and stack.

Immune ageing

Preclinical evidence only

Targets immunosenescence rather than tissue ageing. Thymosin alpha-1 is an approved immunomodulator in a number of countries with a real clinical record in hepatitis B and as a vaccine adjuvant, and has been investigated for T-cell function in older adults.

What is not established: Thymosin alpha-1’s approvals are for specific infectious-disease indications, not ageing. Humanin has no human trial data. The combination is untested.

Metabolic and skin ageing

Preclinical evidence only

Uses tesamorelin — an FDA-approved GHRH analogue for HIV-associated lipodystrophy, and therefore one of the few compounds on this page with a real regulatory file — as the GH-axis element, combined with NAD+, GHK-Cu and MOTS-C.

What is not established: Tesamorelin’s approval is narrow and specific; its visceral-fat data does not generalise to ageing endpoints in healthy people. MOTS-C remains preclinical and the combination is unstudied.

Mobility and connective-tissue ageing

Community practice only

The mobility-oriented longevity combination, pairing the Khavinson bioregulators Cartalax and Epitalon with mitochondrial and redox support.

What is not established: The bioregulator literature underpinning both Cartalax and Epitalon is thin and has not been independently replicated. There is no controlled evidence for this combination or for its individual components on mobility outcomes.

Fat loss and body-composition stacks (6)

The only category containing compounds with phase-3 human efficacy data, alongside several with none at all. The gap between those two groups is wide, so read the grades closely.

Cagrilintide + Semaglutide (CagriSema)

Human data on the combination

The one combination on this page that has been trialled as a combination. Semaglutide is a GLP-1 receptor agonist and cagrilintide a long-acting amylin analogue; the two act on different satiety pathways, and the fixed-dose combination has been evaluated in the phase-3 REDEFINE programme with published weight-loss results.

What is not established: Trial results were below some market expectations and the combination is not FDA-approved as of this review date. Gastrointestinal adverse effects are common with this drug class. Compounded or research-market versions are not the trialled formulation.

GH axis + appetite and fat oxidation

Community practice only

Combines four different proposed mechanisms: GHRH-driven lipolysis, monoamine reuptake inhibition for appetite (tesofensine), NNMT inhibition (5-Amino-1MQ) and a GH-fragment analogue (AOD-9604).

What is not established: AOD-9604 failed to beat placebo for weight loss in a phase-2b human trial — this is one of the few clear negative human results in the peptide space, and it is frequently omitted from marketing. 5-Amino-1MQ has no human efficacy data. Tesofensine is not approved in the US or EU.

Interaction note: Tesofensine is a centrally acting monoamine reuptake inhibitor with cardiovascular and psychiatric signals in trials; it does not belong in the same risk category as the other three.

Visceral fat reduction

Preclinical evidence only

Anchored on tesamorelin, which has FDA approval specifically for reducing excess visceral abdominal fat in HIV-associated lipodystrophy and therefore a genuine human efficacy dataset for that endpoint.

What is not established: Tesamorelin’s data is in a specific patient population, and visceral fat returns after discontinuation. The two compounds added to it have no supportive human efficacy data, and AOD-9604 has a negative phase-2b result.

Mitochondrial fat oxidation

Preclinical evidence only

A mechanism-first combination targeting fat oxidation rather than appetite. SLU-PP-332 is an ERR agonist that has produced exercise-mimetic metabolic effects in rodents; MOTS-C has rodent data on metabolic homeostasis.

What is not established: SLU-PP-332 is an early-stage research chemical with no human data whatsoever and no established safety profile. This is among the least characterised entries on this page.

Incretin + mitochondrial recomposition

Preclinical evidence only

Pairs retatrutide — a triple GIP/GLP-1/glucagon receptor agonist with substantial phase-2 human weight-loss results — with two compounds proposed to act on cellular metabolism, on the reasoning that appetite reduction and energy expenditure are separate levers.

What is not established: Retatrutide is an investigational drug still in phase-3 trials and is not approved anywhere. Neither of the other two has human efficacy data. Whether anything is added to retatrutide alone is entirely unknown.

NAD+ and substrate metabolism

Preclinical evidence only

Approaches body composition through redox cofactor availability and insulin sensitivity rather than appetite suppression.

What is not established: Human NAD+ precursor trials have consistently raised NAD+ levels without demonstrating meaningful body-composition change. 5-Amino-1MQ’s NNMT-inhibition results are rodent-only.

Metabolic and mitochondrial-energy stacks (5)

Built around MOTS-C, Humanin, NAD+ precursors and NNMT inhibition. Mechanistically coherent; almost entirely preclinical.

MOTS-C + Humanin

Preclinical evidence only

The two best-characterised mitochondrial-derived peptides, discussed together because they are encoded in mitochondrial DNA, both decline with age, and appear to act on complementary stress-response and metabolic pathways. This is the base pairing most other stacks in this category build on.

What is not established: Both are preclinical. MOTS-C’s metabolic results come largely from mouse models; Humanin’s cytoprotective work is mostly in vitro. Neither has completed a human efficacy trial.

Mitochondrial energy and endurance

Preclinical evidence only

The most mechanistically layered energy combination: cardiolipin stabilisation (elamipretide), mitochondrial signalling (MOTS-C), redox cofactor supply (NAD+) and NNMT inhibition (5-Amino-1MQ).

What is not established: Only elamipretide has human trial data, in mitochondrial disease rather than performance, with mixed results. Four overlapping mechanisms also means four sets of unknown interactions.

NAD+ + MOTS-C + 5-Amino-1MQ

Preclinical evidence only

A narrower version of the same idea, focused on NAD+ availability. NNMT inhibition is proposed to spare nicotinamide from methylation and clearance, which is the stated reason 5-Amino-1MQ appears alongside NAD+ so often.

What is not established: The NNMT-sparing rationale is plausible but has not been demonstrated to change functional outcomes in humans. No trial data on the combination.

Metabolic flexibility

Preclinical evidence only

Targets the ability to switch between carbohydrate and fat as fuel, using an ERR agonist alongside mitochondrial-derived peptides.

What is not established: SLU-PP-332 has no human data and no established safety profile; AOD-9604 has a negative human weight-loss trial. This combination is mechanistic reasoning, not evidence.

GH axis + mitochondrial signalling

Preclinical evidence only

Adds the GH-secretagogue pair to the mitochondrial base pairing, on the reasoning that GH influences substrate use and body composition alongside the cellular pathways the other two target.

What is not established: GH elevation has known metabolic trade-offs, including reduced insulin sensitivity, which runs against the stated metabolic goal. Untested as a combination.

Cognitive, mood and sleep stacks (6)

Semax and Selank carry decades of clinical use in Russia but little Western trial data. The sleep combinations are mechanistic proposals rather than tested protocols.

Semax + Selank

Human data on each component

The standard nootropic pairing. Semax is an ACTH(4-10) fragment analogue and Selank a tuftsin analogue; both were developed in Russia, where they are registered and prescribed, and they are combined on the reasoning that Semax addresses focus and Selank anxiety, covering stimulation and calming together.

What is not established: Both have human clinical use, but essentially all of it is Russian-language, from the developing institutions, and has not been independently replicated in Western randomised trials. Neither is approved in the US or EU. The combination itself is untested.

Semax + Selank + Epitalon

Preclinical evidence only

Adds Epitalon to the nootropic pair, motivated by its proposed pineal and circadian effects — the reasoning being that sleep quality underpins the cognitive and mood targets of the other two.

What is not established: Epitalon’s circadian and melatonin claims rest on a small, non-replicated literature. Adding a third compound with weaker evidence lowers the grade of the whole combination.

Neurotrophic + cellular energy

Preclinical evidence only

P21 is a small-molecule/peptide compound investigated as a BDNF mimetic in rodent neurogenesis models. It is combined with Semax, also studied for BDNF expression, and MOTS-C for the metabolic side of cognitive endurance.

What is not established: P21 has no human data at all. BDNF-elevation is a mechanistic marker, not a demonstrated cognitive outcome, and rodent neurogenesis results have a poor record of translating.

Neuroplasticity and neural repair

Preclinical evidence only

Substitutes GHK-Cu for MOTS-C, citing its gene-expression work — GHK-Cu has been reported to modulate a large number of genes in cultured cells, including some associated with neural repair.

What is not established: The GHK-Cu gene-expression findings are in cell culture and their in-vivo relevance is unclear; GHK-Cu’s human evidence is dermatological. No human data on P21 or on this combination.

Sleep and overnight recovery

Community practice only

The main sleep-oriented combination. DSIP (delta sleep-inducing peptide) was isolated from rabbit brain in the 1970s and named for its effect on delta-wave sleep; the no-DAC form of CJC-1295 is chosen for its shorter action, on the reasoning that GH release should follow the natural overnight pulse rather than being sustained.

What is not established: DSIP’s human sleep evidence is sparse, decades old and inconsistent; several later attempts to reproduce the original findings failed. There is no controlled data on this combination or on GH secretagogues improving sleep architecture.

Neuroprotection and cognitive resilience

Preclinical evidence only

Approaches cognition through cellular energetics rather than neurotransmitters, on the basis that neurons are metabolically demanding and both NAD+ and Humanin are involved in mitochondrial stress responses.

What is not established: NAD+ precursor trials have not demonstrated cognitive benefit in humans. Humanin has no human trial data. Untested as a combination.

Immune-research stacks (5)

Thymosin alpha-1 is an approved immunomodulator in several countries, which makes these combinations better anchored than most — though still untested as combinations.

Immune resilience and cellular energy

Preclinical evidence only

Thymosin alpha-1 is a 28-amino-acid thymic peptide approved in a number of countries for hepatitis B and used as a vaccine adjuvant, with a real clinical literature on T-cell function. It is paired here with compounds proposed to support the cellular energy that immune activation demands.

What is not established: Thymosin alpha-1’s evidence is indication-specific; it does not establish benefit in healthy people. MOTS-C is preclinical. The combination is untested.

Inflammation and tissue healing

Preclinical evidence only

Combines the immune-modulating peptide with the tissue-repair pairing, discussed where inflammation and healing are seen as the same problem.

What is not established: Immune modulation is not uniformly desirable and depends entirely on context. BPC-157 and TB-500 remain preclinical, and there is no data on this combination.

Antimicrobial peptide research

Preclinical evidence only

LL-37 is the only human cathelicidin and has direct antimicrobial and immunomodulatory activity in laboratory work. It is combined here with thymosin alpha-1 for adaptive-immune support.

What is not established: LL-37 is a double-edged molecule: it has been implicated in the pathology of psoriasis, rosacea and lupus, so raising it is not a neutral act. No human data supports this combination, and nothing here relates to treating an infection.

Immune support + GH axis

Preclinical evidence only

Adds GH secretagogues on the reasoning that the thymus and GH axis interact — GH has documented effects on thymic function, and thymic involution is a feature of immune ageing.

What is not established: The GH-thymus relationship is real but has not been translated into an effective clinical intervention. This combination has no supporting data.

Immune ageing and inflammation

Preclinical evidence only

Targets chronic low-grade inflammation associated with ageing, combining the immune peptide with mitochondrial-derived peptides and GHK-Cu.

What is not established: Three of the four are preclinical for this purpose. The concept is a hypothesis about ageing biology, not a tested intervention.

Skin and cosmetic-research stacks (4)

GHK-Cu has the strongest human cosmetic literature of any peptide on this page. The combinations around it are extrapolations from that single-agent work.

GLOW + cellular ageing

Preclinical evidence only

Extends the GLOW blend with the two most common longevity peptides, on the reasoning that skin appearance and cellular ageing share upstream drivers.

What is not established: GHK-Cu’s genuine human evidence is topical and cosmetic — creams and serums, not injections — and does not transfer to systemic use. Neither MOTS-C nor Epitalon has human skin data.

GLOW + GH axis

Preclinical evidence only

Adds GH secretagogues to the GLOW blend, citing GH and IGF-1 involvement in collagen synthesis and dermal thickness.

What is not established: The GH-collagen link is established physiologically but has not been shown to produce a worthwhile cosmetic result from secretagogue use. Six compounds by count, none studied together.

Pigmentation and skin remodelling

Human data on each component

Melanotan I (afamelanotide) is an alpha-MSH analogue approved in the EU and US for erythropoietic protoporphyria — one of the few approved peptides in this space. It is paired with GHK-Cu, which has the strongest human cosmetic data of any peptide here.

What is not established: Afamelanotide’s approval is for a rare photosensitivity disorder, not cosmetic tanning; unsupervised use raises melanoma-surveillance concerns because it darkens existing lesions. GHK-Cu’s data is topical. The pairing is untested.

Interaction note: Any compound that changes pigmentation complicates visual skin-cancer screening. This is a documented concern with the melanotan class, not a theoretical one.

Cartilage and cosmetic remodelling

Community practice only

A hybrid combination proposed to address cartilage matrix and dermal collagen at once, on the reasoning that both are collagen-dependent connective tissues.

What is not established: Cartalax has essentially no independent evidence base. Shared collagen biology does not imply a shared intervention works for both. No data on this combination.

Hormonal and reproductive-research stacks (4)

Kisspeptin-10 has genuine human endocrine research behind it. What these combinations claim to add on top of that is not established.

Kisspeptin + GH axis

Human data on each component

Kisspeptin-10 is a genuine object of academic endocrine research: it acts upstream of GnRH and has been studied in human trials at Imperial College and elsewhere for reproductive-axis signalling. It is combined here with GH secretagogues to address two hormonal axes.

What is not established: Kisspeptin’s human research is mechanistic and diagnostic rather than therapeutic, typically using acute infusion in controlled settings. Nothing establishes benefit from repeated use, and the combination is untested.

Reproductive-axis and tissue research

Preclinical evidence only

Pairs the reproductive-axis peptide with the tissue-repair combination, citing vascular and inflammatory contributions to reproductive tissue health.

What is not established: There is no human fertility data for any of these compounds used this way. Fertility is a clinical domain with established evidence-based treatments; nothing here belongs in that category.

Sexual-function research

Preclinical evidence only

PT-141 (bremelanotide) is FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women, making it one of the few approved compounds on this page. Kisspeptin has separate human data on sexual-response brain activity.

What is not established: Bremelanotide’s approval is narrow and its trial benefit was modest; nausea and transient blood-pressure increases are common. 5-Amino-1MQ has no relevant human data. Combining two melanocortin-active compounds (bremelanotide and afamelanotide) is not something any study has examined.

Interaction note: Bremelanotide and Melanotan I both act on melanocortin receptors, so their effects are not independent — this is redundancy rather than synergy, with an additive side-effect profile.

Endocrine and mitochondrial support

Preclinical evidence only

Combines the reproductive-axis peptide with mitochondrial-derived peptides, on the reasoning that endocrine tissue is metabolically active and mitochondrial function influences steroidogenesis.

What is not established: The mitochondria-steroidogenesis link is real cell biology but does not establish that these compounds improve endocrine outcomes. No data on the combination.

Peptide stack FAQ

What is a peptide stack?

A peptide stack is two or more peptides used together, chosen because they act on different mechanisms relevant to one research goal. The term is borrowed from bodybuilding rather than from pharmacology. Most named stacks come from research-community practice and vendor marketing, not from studies of the combination.

Are peptide stacks clinically studied?

Almost never as combinations. Individual peptides may have preclinical or human data, but the specific pairings discussed in research communities have generally not been evaluated together in controlled trials. Of the 46 combinations catalogued on this page, one — cagrilintide with semaglutide — has phase-3 data on the combination itself.

Which peptides should not be stacked?

There is no published compatibility table, because the combinations have not been studied. Two patterns warrant particular caution: compounds acting on the same receptor family, where effects are redundant rather than additive but side effects still accumulate, and combinations mixing an investigational compound with an approved drug, where the approved drug’s established profile no longer applies.

What is the Wolverine peptide stack?

The Wolverine stack is a community nickname for BPC-157 combined with TB-500, named after the comic-book character’s healing rather than any clinical protocol. Some clinics use the same name for a four-compound version adding CJC-1295 and ipamorelin, so the label does not reliably indicate composition.

What peptides are in the GLOW stack?

GLOW commonly refers to a premixed blend of GHK-Cu, BPC-157 and TB-500 in one vial. It is a market name rather than a standardised formulation, so ratios vary between suppliers and are often undisclosed.

What is the difference between GLOW and KLOW?

KLOW is GLOW plus KPV. GLOW is GHK-Cu, BPC-157 and TB-500; KLOW adds KPV, the C-terminal tripeptide of alpha-MSH investigated in preclinical models for anti-inflammatory signalling. The K at the start of the name is the KPV.

Why are CJC-1295 and ipamorelin discussed together?

They raise growth hormone through different receptors — CJC-1295 is a GHRH analogue, ipamorelin a selective ghrelin-receptor agonist — so the combination produces a larger GH response than either alone. That the resulting GH elevation improves body composition or recovery in healthy adults is not established.

What does DAC mean in CJC-1295?

DAC stands for drug affinity complex, a modification that binds the peptide to serum albumin and extends its half-life to roughly a week, producing sustained GH elevation. CJC-1295 without DAC acts over minutes to hours and is chosen when the intent is to preserve natural pulsatile GH release. The two are not interchangeable.

Can multiple peptides be mixed in one vial?

Premixed blends such as GLOW and KLOW are sold that way, but chemical compatibility over a storage period is rarely demonstrated. GHK-Cu in particular is acidic and copper-bound, and no published study establishes that peptides sharing a vial with it remain intact. The mixing mode of the peptide calculator shows each compound’s concentration at a shared water volume.

Why is the KLOW peptide blue?

The blue colour comes from the copper ion in GHK-Cu, which is a copper-binding tripeptide. GLOW blends are blue for the same reason. Colour indicates the presence of copper, not potency, purity or correct formulation.

How many peptides can be stacked at once?

No evidence-based limit exists, because the combinations have not been studied. Several catalogued combinations contain five or six compounds. Each addition multiplies the unknowns: more possible interactions, more overlapping side-effect profiles, and less ability to attribute any observed effect to a specific compound.

What is the most commonly discussed peptide stack?

BPC-157 with TB-500 — the Wolverine stack — is the most searched and most discussed combination, followed by the premixed GLOW and KLOW blends built around it, and by CJC-1295 with ipamorelin for growth-hormone research.

Compiled by Peptide Library Editorial · Last reviewed Sep 5, 2026 · Last updated Sep 5, 2026 · Version 1

This page catalogues 46 peptide combinations discussed in research communities and describes what is and is not known about each. It is compiled from published literature, public regulatory records and chemical registries. It is not medical advice, it contains no dosing or administration guidance, and none of these combinations is an established protocol. Peptide Library does not sell peptides. Editorial policy · How this is compiled · Report an error